New approach creates synthetic layered magnets with unprecedented level of control over their magnetic properties
Chestnut Hill, Mass. (7/24/2020) – The magnetic properties of a chromium halide can be tuned by manipulating the non-magnetic atoms in the material, a team, led by Boston College researchers, reports in the most recent edition of Science Advances.
The seemingly counter-intuitive method is based on a mechanism known as an indirect exchange interaction, according to Boston College Assistant Professor of Physics Fazel Tafti, a lead author of the report.
An indirect interaction is mediated between two magnetic atoms via a non-magnetic atom known as the ligand. The Tafti Lab findings show that by changing the composition of these ligand atoms, all the magnetic properties can be easily tuned.
“We addressed a fundamental question: is it possible to control the magnetic properties of a material by changing the non-magnetic elements?” said Tafti. “This idea and the methodology we report on are unprecedented. Our findings demonstrate a new approach to create synthetic layered magnets with unprecedented level of control over their magnetic properties.”
Magnetic materials are the backbone of most current technology, such as the magnetic memory in our mobile devices. It is common practice to tune the magnetic properties by modifying the magnetic atoms in a material. For example, one magnetic element, such as chromium, can be replaced with another one, such as iron.
The team studied ways to experimentally control the magnetic properties of inorganic magnetic materials, specifically, chromium halides. These materials are made of one Chromium atom and three halide atoms: Chlorine, Bromine, and Iodine.
The central finding illustrates a new method of controlling the magnetic interactions in layered materials by using a special interaction known as the ligand spin-orbit coupling. The spin-orbit coupling is a property of an atom to re-orient the direction of spins – the tiny magnets on the electrons – with the orbital movement of the electrons around the atoms.
This interaction controls the direction and magnitude of magnetism. Scientists have been familiar with the spin-orbit coupling of the magnetic atoms, but they did not know that the spin-orbit coupling of the non-magnetic atoms could also be utilized to re-orient the spins and tune the magnetic properties, according to Tafti.
The team was surprised that they could generate an entire phase diagram by modifying the non-magnetic atoms in a compound, said Tafti, who co-authored the report with fellow BC physicists Ying Ran and Kenneth Burch, post-doctoral researchers Joseph Tang and Mykola Abramchuk, graduate student Faranak Bahrami, and undergraduate students Thomas Tartaglia and Meaghan Doyle. Julia Chan and Gregory McCandless of the University of Texas, Dallas, and Jose Lado of Finland’s Aalto University, were also part of the team.
“This finding puts forward a novel procedure to control magnetism in layered materials, opening up a pathway to create new synthetic magnets with exotic properties,” Tafti said. “Moreover, we found strong signatures of a potentially exotic quantum state associated to magnetic frustration, an unexpected discovery that can lead to an exciting new research direction.”
Tafti said the next step is to use these materials in innovative technologies such as magneto-optical devices or the new generation of magnetic memories.
WCLC: Xcovery’s Xalkori challenger shines in phase 3 lung cancer showdown
Xcovery pitted its ALK inhibitor against Pfizer’s Xalkori—the first-ever FDA-approved drug in its class—and came out on top. The drug, ensartinib, shrank tumors in three-quarters of previously untreated lung cancer patients, compared to Xalkori’s 67%, and staved off cancer for two years, more than double the time Xalkori logged.
The phase 3 study tested ensartinib as a firstline treatment against Xalkori (crizotinib) in 290 patients with ALK-positive non-small cell lung cancer. As of July 1, ensartinib had shrunk the tumors of 75% of patients, topping Xalkori’s 67% mark. And even though Xalkori did unusually well in the study, keeping cancer at bay for a median of 12.7 months, Xcovery’s drug trounced it with median progression-free survival of 25.8 months. The median overall survival—how long the drug extended patients’ lives—had not been reached.
“Interestingly, crizotinib overperformed in the study; the duration of response for patients on crizotinib was 27.3 months, which is much higher than what we’ve seen in other studies for patients on crizotinib,” said Leora Horn, M.D., director of the Thoracic Oncology Program and a professor at the Vanderbilt-Ingram Cancer Center, who presented the study.
“It was the best performance ever done by crizotinib in any randomized study” in previously untreated patients, said Xcovery Chief Medical Officer Giovanni Selvaggi, a thoracic oncologist by training who previously worked on Novartis’ ALK inhibitor Zykadia.
Ensartinib also did better than Xalkori in a small group of patients whose disease had spread to the brain. All 11 patients whose brain tumors were large and defined enough to be seen on a scan saw their tumors shrink, Selvaggi said. Seven of the 11 patients (64%) had enough shrinkage to be considered responders, compared to just one-fifth of the 19 patients on Xalkori.
The most common side effect was a sunburn-like rash, “a new toxicity” for ALK inhibitors, Horn said.
“It’s a very benign rash that can be compared to a sunburn and it normally goes away with continued treatment and topical therapies,” Selvaggi said. Unlike the rash that comes with meds that target EGFR, which often gets worse the longer patients take the drug, patients taking ensartinib do not need to stop treatment to get rid of the rash, he added.
The study started enrolling patients who were tested for the ALK mutation in local laboratories but about 40 patients in, it switched over to recruiting those who were centrally tested at larger labs, Horn said. It did this to cut down on false positive results from local testing. Of the 43 patients who were locally tested, 11 were thought to be ALK-positive before central testing showed they were actually negative; seven received ensartinib and two got Xalkori, Horn said.
“Since we only target the ALK protein with this drug, if patients are ALK-negative, it would not be expected to slow tumor growth,” Selvaggi said.
Understandably, the false positive patients would skew the data, so the investigators also reported results for what they called a modified intent-to-treat population of only centrally tested patients. The progression-free survival for this group had not been reached by the data cutoff, meaning more than half of the patients did not see their cancer worsen by then. This figure stayed at 12.7 months for patients on crizotinib.
Up next? Discussing the data with regulators and eventually, a filing: “We are excited to bring an effective and safe new option to patients and their physicians and therefore we are planning to share the data with regulatory agencies as our next step,” Selvaggi said. It’s been a long time coming for the Scripps Florida spinout that made the Fierce 15 class of 2007.
The thing is, if ensartinib can ultimately win approval, it’ll have more drugs to battle than just Xalkori. Roche’s Alecensa, the class’ current sales leader, and Zykadia both topped Xalkori on their way to earning first-line approvals in 2017, and Pfizer’s Lorbrena—Xalkori’s follow-up med—earlier this week posted top-line results showing it could beat out its predecessor, too.
NIH to fund new diagnostic tests for the emerging, severe childhood illness linked to COVID-19
While most children exposed to the novel coronavirus suffer only a mild infection, others may develop a rare but severe reaction that attacks several organs at once, requiring intensive rescue care.
To better diagnose this complication of COVID-19—known as Multisystem Inflammatory Syndrome in Children, or MIS-C—the National Institutes of Health launched a research funding program that will offer up to $20 million in grants over the next four years.
MIS-C can be fatal, and has been shown to affect the heart, lungs, kidneys, brain, skin and eyes. A study by the Centers for Disease Control and Prevention tracking a group of MIS-C patients—at a median age of eight years old—showed 80% required intensive care, with many receiving ventilator support and treatments for circulatory shock.
Most had tested positive for COVID-19 by either molecular or antibody tests, but early signs and symptoms can range from almost none at all to those seen and unseen—such as fever and cough, or abdominal pain and diarrhea, as well as hidden inflammation of the heart’s coronary arteries.
The NIH’s new effort aims to incorporate new diagnostics for the different genetic, immune, viral and environmental factors that may help predict a child’s chances of progressing to MIS-C.
“We urgently need methods to distinguish children at high risk for MIS-C from those unlikely to experience major ill effects from the virus, so that we can develop early interventions to improve their outcomes, ” said Diana Bianchi, director of the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The institute’s project—dubbed PreVAIL kIds, for Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence—dovetails with the NIH’s “Shark Tank-like” Rapid Acceleration of Diagnostics initiative, which recently advanced seven projects to its final phases.
PreVAIL kIds will support studies to evaluate genes and other pediatric biomarkers, and projects using machine learning techniques to help develop new tests, by gathering funds from multiple NIH institutes and centers focused on related organs, diseases and determinants of health.
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Biogen’s aducanumab is inching closer to an FDA decision. The Big Biotech, along with partner Eisai, announced on Friday that the FDA accepted its regulatory submission for aducanumab, its once-failed Alzheimer’s drug—with priority review to boot.
The agency expects to decide the fate of the treatment by March 7, 2021. Along the way, it will hold an advisory committee meeting. It has not set a date for the meeting, but Jefferies analyst Michael Yee expects it sometime in the first quarter of 2021.
How the FDA rules on aducanumab will show how far the FDA and its commissioner, Stephen Hahn, M.D., are willing to diverge from its established approval standards. Under U.S. law, companies need to show “substantial” evidence of effectiveness to win approval.
Aducanumab has had a bumpy ride, failing a futility analysis in March 2019, which led Biogen to axe its phase 3 program. Eight months later, the company resurrected the drug saying the analysis was “incorrect,” arguing that it was based on a smaller dataset that featured fewer patients who received high-dose aducanumab. Adding in the additional data showed aducanumab reduced clinical decline, the company said.
Biogen believes that, if approved, aducanumab would become the first treatment to slow decline in people with Alzheimer’s disease, a neurodegenerative disorder whose treatments focus on controlling symptoms. The data, however, are not so clear. In Yee’s words, “the phase 3 data was largely mixed and still inconclusive.”
The data underpinning the filing come from a phase 1b study, as well as a pair of phase 3 studies that tested aducanumab in patients with early-stage and mild Alzheimer’s. The phase 3 results were mixed, with one study suggesting that aducanumab is no better than placebo, while the other linked the drug to improved scores on a dementia scale.
Patients who received the highest dose of aducanumab in a phase 3 trial dubbed EMERGE showed statistically significant improvement on a clinical dementia scale. But the same patient group in the ENGAGE phase 3 study did worse than patients taking placebo on that same measure, as well as on a test of cognitive function.
Biogen did not use a priority review voucher to snag a speedy review, “suggesting FDA sees this as an unmet need and willing to review this under an accelerated window,” Yee wrote in an investor note.
Optimists argue that the speedy review suggests the agency is “comfortable with the totality of the data, recognizes high unmet need, and really wants to get an Alzheimer’s drug approved,” Yee wrote. Others might read less into the priority review, as the FDA could still ask Biogen for more data or extend their review period.
Some analysts have been cautiously optimistic. Cantor Fitzgerald’s Alethia Young wrote earlier this year that she was “reasonably confident” the FDA would accept aducanumab’s application, adding the caveat that she and her colleagues “don’t view this approval as certain,” given “the complicated issues around the statistical analysis and the inconsistent outcomes from both pivotal trials.” Brian Abrahams of RBC Capital Markets estimated a 30% chance the FDA would approve the drug “despite the mixed ph.III data.”
But Baird analyst Brian Skorney has dismissed aducanumab’s chances, saying the bulk of the data shows aducanumab doesn’t provide a clinical benefit.
“If Biogen said based on this data it was running another study, the stock would be down because the data doesn’t justify investing in another study. The regulatory threshold is higher than that,” Skorney wrote in December. “The bottom line is, the FDA standard of approval is substantial evidence of efficacy and the cumulative data for aducanumab falls really far of this standard.”
Impacts of Artificial Intelligence in Content Writing
Hong Kong media tycoon Jimmy Lai arrested under security law
How to make a cannabis-infused canna-grapefruit spritz
Could Joe Biden budge on cannabis legalization?
4 weed products Weldon Angelos can’t live without
A $15K Bitcoin Likely As Price Breaks Above “Multi-Year Bullish Triangle”
Ethereum Classic Under Multiple 51% Attacks | Bitcoin News Summary Aug 10, 2020
Chinese Tesla rival Xpeng Motors files for New York IPO
U.S. health chief offers Taiwan ‘strong’ support in landmark visit
Stock futures mixed after Trump signs orders extending coronavirus relief
Number of Bitcoin Cash Whales Drop Following 39% Price Surge
Bitcoin Price Tackles $12,000 After Breaking Through a Key Resistance Zone
Japanese Messaging Giant LINE’s LN Token Trading on BitMax
Bitcoin Erupts Past $12,000: Here’s What Analysts Think Comes Next
Some office space could get permanently cut during the pandemic. Here’s how companies will cope
Here’s Why Analysts Are Expecting For Ethereum To Drop Back Towards $370
Pelosi slams Trump’s executive actions on coronavirus relief: ‘Absurdly unconstitutional’
Hyundai launches Ioniq as a standalone brand to exclusively make electric cars
How Miners Can Hedge Their Inventory to Increase Return on Investment
Analysts Expect Chainlink (LINK) Reversal After 50% Eruption to $14
BAND Token is Now Available for Trading on Huobi Global
Amazon reportedly discussing using former J.C. Penney and Sears stores as fulfillment centers
DeFi has more than just yield farming to thank for the recent surge
Judge denies bail for men accused of sneaking Carlos Ghosn out of Japan
What Hope Do Bears Have If Bitcoin Holds $11,500? Analyst Asks
Cardano short/medium-term price analysis: August 09
U.S. tops 5 million coronavirus cases as outbreak threatens America’s Midwest
School buses are another coronavirus question mark
Will Bitcoin be the go-to asset during the incoming stagflation?
5 Thing You Can Do To Make Your Weeks Run Smoother
Max Verstappen wins 70th Anniversary Grand Prix at Silverstone
Economic Crisis Leaves US Government Officials in State of Confusion
Litecoin short-term price analysis: 09 August
This ‘Hoverboard’ can transform into a rideable 4-wheeler
Bitcoin: What to expect during institutional ‘land grab’ phase?
LINK Trading Volume Surpasses Bitcoin on Coinbase
While some techies flee Silicon Valley, this Waymo engineer is doubling down and running for office
Bitcoin’s price surge has depleted long-term hodlings
The Top Dice Strategies That Actually Make You Money
Stanley Brothers Face Another Setback with Final Refusal of “CW” Trademark
AI1 week ago
Deploying a server for Rasa X chatbot
AR/VR1 week ago
Onward On Oculus Quest Review: Lock And Load Without Wires
AR/VR1 week ago
Polybius Dev’s Next Psychedelic VR Game Is Moose Life, Arrives In August
AI1 week ago
Three AI companies join a business development group built by the London Stock Exchange
AI1 week ago
An automated health care system that understands when to step in
AI1 week ago
8 Ways How AI is Transforming the Sports Industry?
Automotive1 week ago
Gestamp records H1 net income loss of EUR120m
Energy1 week ago
Longhorn Solar Chosen by Retail Energy Provider Griddy as One of Three Solar Panel Installation Partners